Related references
Note: Only part of the references are listed.The WOEST 2 registry A prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention
A. J. W. M. de Veer et al.
NETHERLANDS HEART JOURNAL (2022)
Evolving Antithrombotic Treatment Patterns for Patients With Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome or Underwent Percutaneous Coronary Intervention in China: A Cross-Sectional Study
Ni Suo et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)
Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease
Hsin-Fu Lee et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gerhard Hindricks et al.
EUROPEAN HEART JOURNAL (2021)
Comparing Safety and Efficacy of Rivaroxaban with Warfarin for Patients after Successful Stent Placement for Chronic Iliofemoral Occlusion: A Retrospective Single Institution Study
Xing Zhang et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2021)
Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease
Anders Gottsaeter
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
What is Standard Dose of Rivaroxaban in Elderly Asian Patients with Atrial Fibrillation: 20ms versus. 15mg?
Sung Soo Kim et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2021)
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease
Craig Coleman et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2020)
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: a Systematic Review and Meta-Analysis
Xiang-Zhong Liao et al.
CARDIOVASCULAR DRUGS AND THERAPY (2020)
Editor's Choice-2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
Victor Aboyans et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2018)
Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
Daniele Pastori et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Antiplatelet and anticoagulant for prevention of reocclusion in patients with atrial fibrillation undergoing endovascular treatment for low extremity ischemia
Liangxi Yuan et al.
JOURNAL OF THORACIC DISEASE (2018)
Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report
Gregory Y. H. Lip et al.
CHEST (2018)
Safety and efficacy of rivaroxaban compared with warfarin in patients undergoing peripheral arterial procedures
Anjan Talukdar et al.
JOURNAL OF VASCULAR SURGERY (2017)
Rivaroxaban vsWarfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke A Randomized Clinical Trial
Keun-Sik Hong et al.
JAMA NEUROLOGY (2017)
Peripheral arterial disease is associated with an increased risk of atrial fibrillation in the elderly
William F. Griffin et al.
EUROPACE (2016)
Atrial fibrillation is a risk marker for worse in-hospital and long-term outcome in patients with peripheral artery disease
Kristina Wasmer et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF
William Schuyler Jones et al.
EUROPEAN HEART JOURNAL (2014)
Feasibility and Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation
Dhanunjaya Lakkireddy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
Ron Pisters et al.
CHEST (2010)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)